30 July, 2017
DENTSPLY SIRONA Inc. (XRAY), a part of Healthcare sector and belongs to Medical Instruments & Supplies industry; ended its day with gain 0.57% and finalized at the price of $63.05. (NASDAQ:XRAY) by 99.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
COPYRIGHT VIOLATION NOTICE: "DENTSPLY SIRONA Inc".
A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in DENTSPLY SIRONA by 2.7% in the first quarter. Atria Investments LLC boosted its position in shares of DENTSPLY SIRONA by 1.5% in the second quarter. Penserra Capital Management LLC increased its position in DENTSPLY SIRONA by 9.5% in the first quarter. Clearbridge Investments LLC now owns 5,258,060 shares of the medical instruments supplier's stock valued at $328,313,000 after buying an additional 1,353,040 shares in the last quarter. TNB Financial acquired a new position in shares of DENTSPLY SIRONA during the first quarter valued at approximately $259,000. Finally, Renaissance Technologies LLC increased its position in DENTSPLY SIRONA by 246.0% in the first quarter. Renaissance Technologies LLC now owns 1,044,558 shares of the medical instruments supplier's stock valued at $65,222,000 after buying an additional 742,700 shares in the last quarter. Institutional owners hold 97.50% stake in the company, while insiders ownership held at 0.70%.
Shares of DENTSPLY SIRONA Inc. The 50 day SMA of the stock is price of $64.03 and a two hundred day SMA of $62.05. The stock is now trading -5.97% away from the 52-week high and separated 65.38% from the 52-week low. The firm has a market capitalization of $14.45 billion, a price-to-earnings ratio of 40.57 and a beta of 1.27.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Tuesday, May 9th.
Last time, the company failed Wall Street by reporting EPS of $0.49, smashing the consensus of $0.50 per share. Currently, DENTSPLY SIRONA Inc.net profit margin for the 12 months is at 9.44%. The company had revenue of $900.50 million for the quarter, compared to the consensus estimate of $916.55 million. The company's stock has a normal trading capacity of 1.25M shares while the relative volume is 0.96. The business's revenue was up 16.6% on a year-over-year basis. On average, analysts expect that DENTSPLY SIRONA will post $2.84 earnings per share for the current year. The dividend will be $0.088 per share for the quarter or $0.35 on an annualized basis. Thestreet.com's news article titled: "Sirona Dental Systems (SIRO) Stock Falls Following Dentsply Merger" with publication date: September 16, 2015 was also an interesting one. The value of the investment in DENTSPLY SIRONA Inc. increased from $22,722,000 to $29,572,000 a change of $6,850,000 for the reporting period.
WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & global trademark and copyright legislation.
DENTSPLY SIRONA Inc. shares had a trading volume of 70K by the end of trading on Friday.
Several equities analysts recently commented on the stock. Moreover, De Burlo Group Inc has 0.7% invested in the company for 49,650 shares. Credit Suisse Group restated an "outperform" rating and set a $75.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a report on Thursday, July 13th. Cleveland Research upgraded DENTSPLY SIRONA from a "neutral" rating to a "buy" rating in a report on Tuesday, May 23rd. The latest reports which are outstanding on Wednesday 26th of July state 6 analysts have a rating of "strong buy", 4 analysts "buy", 5 analysts "neutral", 1 analysts "sell" and 0 analysts "strong sell". Finally, HC Wainwright initiated coverage on DENTSPLY SIRONA in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. On November 1 the stock rating was upgraded from "Equal-weight" to "Overweight" with a current price target of $69.00 in an announcement from Morgan Stanley. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. Additionally, its consumable medical device products are used for urological and surgical applications.